Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Stray Dog Becomes the Star of a Wrestling Match
‘Cat Distribution System’ Strikes at Chicago Airport, Leading Man Who Missed Flight to Fly Home With Kitten
Caught on Camera: Rogue Banana Witnesses Car Crash and Springs Into Action
Flatmates Who Game: Setting Up a Shared Minecraft Space
Strangers Online, Friends in Need: The Heart of Gaming Communities
Dad Kept a Handmade Paper Tie His Daughter Made at Age 5 for a Very Special Moment
Strangers Push a Train to Rescue Trapped Man
At 90 Years Old, James Thomas Completed His 43rd NYC Marathon, His Last One
High School Band Student Goes Viral With Incredible 'Thunderstruck' Xylophone Performance
He Found a Baby in a Phone Booth. Years Later, She Found Him and Calls Him Dad
